family with sequence similarity 218 member AGenealiases: C4orf39 · TRIM61-AS1
Q-omics provides the consensus-scored FAM218A profile across patient tissues and cancer cell-line models. FAM218A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FAM218A is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, FAM218A RNA expression shows 17,919 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, THCA, and UVM as cancer lineages where FAM218A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM218A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM218A survival associations across molecular data types. FAM218A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM218A RNA expression–survival associations across cancer types. High FAM218A expression shows unfavorable associations in MESO, UCEC and KIRC, but favorable associations in UCS, KIRP and OV. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for FAM218A RNA expression.
This table summarizes FAM218A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM218A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM218A shows lower tumor expression in THCA, COAD, LUAD, KICH, READ and UCEC. The THCA box plot shows higher FAM218A RNA expression in normal versus tumor tissue (log2 FC = −1.688, t-test p < 0.001).
This table shows molecular features associated with FAM218A in patient tissues and cancer cell lines. In patient samples, FAM218A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM218A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
